| NKCx Histopathological outcome* within 12 months after cervix cytology in 2024 |
| 241 Kronoberg |
| Benign | LSIL | HSIL | AIS | Cancer | Other | PAD missing | Total | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cytologi | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel | Antal | Andel |
| Benign sample | 54 | 2.3% | 5 | 0.2% | 16 | 0.7% | . | . | . | . | 1 | 0.0% | 2299 | 96.8% | 2375 | 100.0% |
| ASCUS | 30 | 28.3% | 17 | 16.0% | 18 | 17.0% | 3 | 2.8% | . | . | 1 | 0.9% | 37 | 34.9% | 106 | 100.0% |
| LSIL | 11 | 20.8% | 11 | 20.8% | 10 | 18.9% | . | . | . | . | 1 | 1.9% | 20 | 37.7% | 53 | 100.0% |
| Atypical glandular cells/AGC | 1 | 33.3% | . | . | 2 | 66.7% | . | . | . | . | . | . | . | . | 3 | 100.0% |
| Unclear atypia | . | . | . | . | 1 | 100.0% | . | . | . | . | . | . | . | . | 1 | 100.0% |
| ASC-H | 4 | 25.0% | 1 | 6.3% | 11 | 68.8% | . | . | . | . | . | . | . | . | 16 | 100.0% |
| HSIL | . | . | 2 | 11.8% | 12 | 70.6% | . | . | 1 | 5.9% | . | . | 2 | 11.8% | 17 | 100.0% |
| Totalt | 100 | 3.9% | 36 | 1.4% | 70 | 2.7% | 3 | 0.1% | 1 | 0.0% | 3 | 0.1% | 2358 | 91.7% | 2571 | 100.0% |
| NOTE: Histopathological outcome from T83x taken into account. |
| This list includes only one diagnosis (the highest ranking) per person, applies to both Cyt and Pad. |
| * Harmonization of PAD codes classification between analysis registry and process registry has been carried out. PAD Class 0 (non diagnostic, unreasonable diagnosis) is excluded, and next PAD counts instead. |
| The classes 2a, b, c and 3a (suspected premalignant, pre-malignant UNS, HPV, suspected malignant) are grouped into 'Other'. |
| Process Registry's Class 1 (benign), 2d (LSIL) and 3b (manifest cancer) have all been introduced without exception. Some codes that occur beyond the scope of the process registry has been added to the different categories. |
| Snomed codes in the category Cancer: |
|---|
| M80703 |